Acute renal failure when exenatide is co-administered with diuretics and angiotensin II blockers

Pharmacy World and Science

Volumn 32, Issue 5, 2010, Pages 559-561

  López Ruiz, Alfonso ^a   Del Peso Gilsanz, Cristina ^a   Meoro Avilés, Amparo ^a   Soriano Palao, José ^a   Andreu, Alberto ^a   Cabezuelo, Juan ^a   Arias, José L ^b  

^a HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

^b UNIVERSITY OF GRANADA   (Spain)

Author keywords

ADE; Adverse drug effect; Angiotensin II receptor antagonist; Candesartan; Combined therapy; Diuretic; Exenatide; Hydrochlorothiazide; Ischemic acute renal failure; Renal function; Type 2 diabetes mellitus

Indexed keywords

ACETYLSALICYLIC ACID; AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ATORVASTATIN; BICARBONATE; C PEPTIDE; CANDESARTAN; CREATININE; DIURETIC AGENT; EXENDIN 4; FENOFIBRATE; HEMOGLOBIN A1C; HYDROCHLOROTHIAZIDE; INSULIN GLARGINE; METFORMIN; OLMESARTAN; POTASSIUM; REPAGLINIDE; SODIUM; TRIACYLGLYCEROL; UREA; URIC ACID;

ACUTE KIDNEY FAILURE; ACUTE KIDNEY TUBULE NECROSIS; ADULT; ARTICLE; CASE REPORT; CREATININE URINE LEVEL; DEHYDRATION; DOSE RESPONSE; DRUG DOSE INCREASE; DRUG WITHDRAWAL; ERYTHROCYTE SEDIMENTATION RATE; HUMAN; KIDNEY FUNCTION TEST; LABORATORY TEST; MALE; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; SODIUM URINE LEVEL; VOMITING;

ACUTE KIDNEY INJURY; ANGIOTENSIN RECEPTOR ANTAGONISTS; DIABETES MELLITUS, TYPE 2; DIURETICS; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; HUMANS; HYPOGLYCEMIC AGENTS; MALE; PEPTIDES; VENOMS; YOUNG ADULT;

EID: 78349307376     PISSN: 09281231     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11096-010-9423-8     Document Type: Article

References (10)

1. MS Fineman TA Bicsak LZ Shen K Taylor E Gaines A Varns, et al. 2003 Effect on glycemic control of exenatide (synthetic exendin-4) additive to existing metformin and/or sulfonylurea treatment in patients with type 2 diabetes Diabetes Care 26 2370 2377 1:CAS:528:DC%2BD3sXmslOktbc%3D 10.2337/diacare.26.8.2370 12882864 (Pubitemid 36993328)
2. OG Kolterman JB Buse MS Fineman E Gaines S Heintz TA Bicsak, et al. 2003 Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting glucose in subjects with type 2 diabetes J Clin Endocrinol Metab 88 3082 3089 1:CAS:528:DC%2BD3sXlslaitr4%3D 10.1210/jc.2002-021545 12843147 (Pubitemid 36877476)
3. SL Norris N Lee S Thakurta BK Chan 2009 Exenatide efficacy and safety: a systematic review Diabet Med 26 837 846 1:CAS:528:DC%2BD1MXht1Gnu7jI 10.1111/j.1464-5491.2009.02790.x 19719703
4. LC Glass Y Qu S Lenox D Kim JR Gates R Brodows, et al. 2008 Effects of exenatide versus insulin analogues on weight change in subjects with type 2 diabetes: a pooled post-hoc analysis Curr Med Res Opin 24 639 644 1:CAS:528:DC%2BD1cXkvValtb0%3D 10.1185/030079908X260862 18218179 (Pubitemid 351428974)
5. D Kim L MacConell D Zhuang PA Kothare M Trautmann M Fineman, et al. 2007 Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes Diabetes Care 30 1487 1493 1:CAS:528:DC%2BD2sXntlWktr4%3D 10.2337/dc06-2375 17353504 (Pubitemid 46871159)
6. CM Edwards SA Stanley R Davis AE Brynes GS Frost LJ Seal, et al. 2001 Exendin-4 reduces fasting and postprandial glucose and decreases energy intake in healthy volunteers Am J Physiol Endocrinol Metab 281 E155 E161 1:CAS:528:DC%2BD3MXltVKhtrg%3D 11404233
7. MC Bunck M Diamant A Cornér B Eliasson JL Malloy RM Shaginian, et al. 2009 One-year treatment with exenatide improves beta-cell function, compared with insulin glargine, in metformin-treated type 2 diabetic patients: a randomized, controlled trial Diabetes Care 32 762 768 1:CAS:528: DC%2BD1MXmt1Wntbo%3D 10.2337/dc08-1797 19196887
8. DM Kendall RM Cuddihy RM Bergenstal 2009 Clinical application of incretin-based therapy: therapeutic potential, patient selection and clinical use Eur J Intern Med 20 S329 S339 1:CAS:528:DC%2BD1MXotFCgtLY%3D 10.1016/j.ejim.2009.05.009 19580952
9. WJ Weise MS Sivanandy CA Block RJ Comi 2009 Exenatide-associated ischemic renal failure Diabetes Care 32 E22 E23 10.2337/dc08-1309 19171732
10. OE Johansen R Whitfield 2008 Exenatide may aggravate moderate diabetic renal impairment: a case report Br J Clin Pharmacol 66 568 569 10.1111/j.1365-2125.2008.03221.x 18537959